Market Cap | 138.27M | P/E | - | EPS this Y | 18.80% | Ern Qtrly Grth | - |
Income | -35.48M | Forward P/E | -3.98 | EPS next Y | 65.40% | 50D Avg Chg | 6.00% |
Sales | 70.99M | PEG | -0.05 | EPS past 5Y | - | 200D Avg Chg | -31.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 74.40% | 52W High Chg | -71.00% |
Recommedations | 1.70 | Quick Ratio | 0.53 | Shares Outstanding | 112.65M | 52W Low Chg | 37.00% |
Insider Own | 8.94% | ROA | -11.29% | Shares Float | 82.58M | Beta | -0.24 |
Inst Own | 77.13% | ROE | - | Shares Shorted/Prior | 3.21M/3.20M | Price | 1.24 |
Gross Margin | 87.84% | Profit Margin | -49.99% | Avg. Volume | 695,608 | Target Price | 3.75 |
Oper. Margin | -12.65% | Earnings Date | May 9 | Volume | 205,013 | Change | 2.07% |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
HC Wainwright & Co. | Buy | Apr 29, 24 |
Lake Street | Buy | Mar 18, 24 |
HC Wainwright & Co. | Buy | Mar 18, 24 |
HC Wainwright & Co. | Buy | Mar 11, 24 |
Lake Street | Buy | Aug 21, 23 |
Piper Sandler | Overweight | Aug 11, 23 |
BMO Capital | Outperform | Nov 14, 22 |
Cantor Fitzgerald | Overweight | Mar 5, 20 |
Cowen & Co. | Outperform | Dec 18, 19 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Mahmoud Ramy A | Chief Executive Offi.. Chief Executive Officer | Jan 31 | Sell | 1.31 | 52,875 | 69,266 | 548,387 | 02/01/24 |
Mahmoud Ramy A | Chief Executive Offi.. Chief Executive Officer | Dec 15 | Sell | 1.15 | 11,114 | 12,781 | 509,728 | 12/20/23 |
Marino Michael F III | Chief Legal Officer.. Chief Legal Officer & Corp Sec | Dec 15 | Sell | 1.15 | 5,005 | 5,756 | 333,511 | 12/20/23 |
Marino Michael F III | Chief Legal Officer.. Chief Legal Officer & Corp Sec | Jan 13 | Sell | 1.77 | 5,241 | 9,277 | 180,353 | 01/17/23 |
Miller Peter K | Chief Executive Offi.. Chief Executive Officer | Jan 13 | Sell | 1.77 | 29,664 | 52,505 | 853,384 | 01/17/23 |
Marino Michael F III | Chief Legal Officer.. Chief Legal Officer & Corp Sec | Dec 15 | Sell | 1.69 | 2,751 | 4,649 | 185,594 | 12/19/22 |
Janis Michele | Acting Chief Financi.. Acting Chief Financial Officer | Dec 15 | Sell | 1.69 | 1,015 | 1,715 | 48,927 | 12/19/22 |
Clavelli Victor M | Chief Commercial Off.. Chief Commercial Officer | Dec 15 | Sell | 1.69 | 3,208 | 5,422 | 199,955 | 12/19/22 |
Miller Peter K | Chief Executive Offi.. Chief Executive Officer | Dec 15 | Sell | 1.69 | 15,253 | 25,778 | 883,048 | 12/19/22 |
Mahmoud Ramy A | President and COO President and COO | Mar 16 | Sell | 2.11 | 8,219 | 17,342 | 195,124 | 03/17/22 |
Marino Michael F III | Chief Legal Officer.. Chief Legal Officer & Corp Sec | Mar 16 | Sell | 2.11 | 4,617 | 9,742 | 149,545 | 03/17/22 |
Goldan Keith A. | Chief Financial Offi.. Chief Financial Officer | Mar 16 | Sell | 2.11 | 4,617 | 9,742 | 141,726 | 03/17/22 |
Clavelli Victor M | Chief Commercial Off.. Chief Commercial Officer | Mar 16 | Sell | 2.11 | 5,705 | 12,038 | 189,693 | 03/17/22 |
Miller Peter K | Chief Executive Offi.. Chief Executive Officer | Mar 16 | Sell | 2.11 | 25,974 | 54,805 | 880,826 | 03/17/22 |
Mahmoud Ramy A | President and COO President and COO | Sep 17 | Sell | 2.79 | 12,499 | 34,872 | 281,765 | 09/17/21 |